A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study is sponsored by Genzyme Japan K.K. The purpose of this study is to assess the
safety, tolerability and pharmacokinetics of Clofarabine (JC0707) intravenously administered
to Japanese adult patients with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia
(AML) at 20, 30, and 40 mg/m2/day on a 5-day dose schedule.